Leveraging our extensive expertise in hepatic disease research, Ace Therapeutics specializes in addressing the challenges of novel drug development for liver diseases. We offer custom preclinical services to support clients' acute liver injury R&D projects, encompassing research model development and validation, biomarker identification and characterization, and development of novel therapeutic agents.
Overview of Acute Liver Injury
Acute liver injury is a severe hepatic disease marked by rapid liver function deterioration within two weeks post-exposure to hepatotoxic factors. Common causes of acute liver injury include drug-induced liver injury (DILI), chemical or toxin exposure, traumatic damage, ischemic injury, and infections.
Fig.1 Various factors leading to liver injury. (Liu Q, et al. 2024)
Leveraging our expertise in liver diseases, we can develop acute liver injury models across species, enabling our clients to conduct a wide range of acute liver injury studies.
- Chemically Induced Models of Acute Liver Injury
- Surgical Animal Models of Acute Liver Injury
- Genetic Models of Acute Liver Injury
- Viral Infection Models of Acute Liver Injury
Drug Development Services for Acute Liver Injury
Drug Target identification and Validation Services
- Transcriptomics and Single Cell RNA Sequencing
Through integrated transcriptomics and single-cell RNA sequencing approaches, we identify the dysregulated pathways involved in liver injury pathogenesis, enabling systematic identification of novel therapeutic targets for acute liver injury intervention.
- Metabolomics Analysis
We employ advanced metabolomic techniques to quantify pathological metabolic alterations in liver injury, including glutathione (GSH) depletion and mitochondrial dysfunction, while identifying potential therapeutic targets.
Drug Screening Services
- Drug Screening in Hepatocyte Injury Models
We leverage both immortalized hepatocyte lines (e.g., HepG2, Huh7) and primary human/rat hepatocytes to establish physiologically relevant liver injury models. These models enable systematic evaluation of candidate compounds' hepatoprotective efficacy through multiple quantitative endpoints.
- High Throughput Screening (HTS)
Our automated high-content screening platform allows rapid identification of lead compounds by simultaneously evaluating candidates against multiple mechanistically validated targets for acute liver injury intervention, significantly accelerating the drug discovery process.
Preclinical Efficacy and Pharmacology Study Services
- Hepatocyte Protection Studies
We establish physiologically relevant hepatocyte injury models using acetaminophen (APAP) or D-galactosamine (D-GalN) treatment, followed by comprehensive quantitative assessment of drug efficacy through multiple parameters including cell viability (CCK-8 assay), membrane integrity (LDH release), and oxidative stress markers (ROS levels) to systematically evaluate hepatoprotective potential.
- Anti-inflammatory & Antioxidant Mechanism Studies
Our integrated platform enables systematic evaluation of compound effects across multiple therapeutic dimensions, including inflammatory modulation (TNF-α and IL-6 secretion profiling), antioxidant capacity (SOD activity and GSH level quantification), and critical signaling pathway regulation (Nrf2/NF-κB activation status) to provide comprehensive mechanistic insights.
- Pharmacodynamic Evaluation in Acute Liver Injury Models
Utilizing well-characterized rodent models of liver injury (e.g., APAP-, D-GalN-, or LPS-induced models), we conduct drug efficacy evaluation through hepatic function analysis, histopathological evaluation, and oxidative stress profiling.
Ace Therapeutics has a team of professionals working in the field of liver diseases. We are able to offer the custom services according to experimental needs of clients. If you would like to learn more about our research services on acute liver injury, please do not hesitate to contact us.
Reference
- Liu, Q.; et al. Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations. Clin Transl Med. 2024, 14(8):e1812.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
